Want to see GB:GDR full AI Analyst Report?

Genedrive (GDR) Price & Analysis

60 Followers

GDR Stock Chart & Stats

0.88 p

0.03 p(1.30%)

At close: Jan 09 4:00 PM EST

0.88 p

0.03 p(1.30%)

Day’s Range― - ―

52-Week Range0.19 p - 1.50 p

Previous CloseN/A

Volume280.42K

Average Volume (3M)49.58M

Market Cap

£16.86M

Enterprise Value7.30M

Total Cash (Recent Filing)£387.00K

Total Debt (Recent Filing)£500.00K

Price to Earnings (P/E)―

Beta-0.81

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding1,605,568,200

10 Day Avg. Volume14,118,826

30 Day Avg. Volume49,583,488

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)5.48

Price to Sales (P/S)10.31

P/FCF Ratio-1.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables RevenueGenedrive’s business model centers on instrument placements plus recurring single-use test cartridges. That installed-base + consumables model creates predictable, high-frequency revenue streams as utilization scales, supporting long-term margin improvement and cash conversion if adoption continues.

Low Financial LeverageThe company carries negligible debt, removing near-term interest and refinancing risk and preserving operational flexibility. With zero reported debt, management can focus on commercialization and scaling without immediate capital servicing burdens, though runway depends on cash generation or equity financing.

Accelerating Revenue GrowthTop-line acceleration in 2025 signals improving commercial traction and adoption of the Genedrive platform. Sustained revenue growth is a durable indicator of market acceptance and supports future consumables pull-through and operational leverage as fixed costs are spread over a larger revenue base.

Bears Say

Persistent Cash BurnOperating and free cash flow remain deeply negative, implying ongoing reliance on external financing. Persistent cash burn constrains strategic options, risks recurrent dilution or covenant pressure, and reduces the effective runway unless revenue scale or gross margins improve materially.

Ongoing Operating LossesThe company continues to report substantial operating losses, indicating the cost base outpaces current revenue. Continued negative EBIT undermines self-funding, makes margin recovery essential for sustainability, and means management must either scale revenue rapidly or materially cut costs to reach breakeven.

Compressed Equity BaseA sharply reduced equity cushion limits the firm’s ability to absorb further losses and increases the likelihood of dilutive capital raises. A thin balance sheet reduces resilience to shocks, heightens funding risk, and can pressure strategic investments needed to build scale and improve margins.

Genedrive News

Genedrive strengthens board with Graham Cole CBE as new chair

Genedrive ( ($GB:GDR) ) has issued an update. Genedrive plc, the Manchester-headquartered AIM-listed point-of-care pharmacogenetic testing specialist, has...

8d ago

Genedrive lifts revenues as NHS and international uptake of rapid genetic tests builds

Genedrive ( ($GB:GDR) ) just unveiled an announcement. Genedrive reported unaudited FY26 income of about £1.4 million, up...

9d ago

Genedrive Wins Ministerial Backing as NHS Expands Rapid Pharmacogenetic Testing

Genedrive ( ($GB:GDR) ) has shared an update. Genedrive has gained high-profile validation for its MT-RNR1 ID Kit...

12d ago

Genedrive launches board shake-up as chairman Ian Gilham steps down

Genedrive ( ($GB:GDR) ) has provided an update. Genedrive plc, headquartered in Manchester, develops and commercialises precision pharmacogenetic...

21d ago

Genedrive expands CYP2C19 diagnostics with Thermo Fisher lab collaboration

Genedrive ( ($GB:GDR) ) has provided an update. Genedrive has signed a collaboration agreement with Thermo Fisher Scientific...

23d ago

Genedrive’s MT-RNR1 Test Adopted as Routine Neonatal Service at Manchester NHS Trust

Genedrive ( ($GB:GDR) ) has shared an announcement. Genedrive plc said Manchester University NHS Foundation Trust has moved...

1M ago

Genedrive Secures £0.76m R&D Tax Credit to Support Expansion of Point-of-Care Genetics

An announcement from Genedrive ( ($GB:GDR) ) is now available. Genedrive plc, a Manchester-headquartered pharmacogenetic diagnostics company focused...

2M ago

Genedrive Reports No Change in Share Option Scheme Balances in Latest Block Listing Return

Genedrive ( ($GB:GDR) ) just unveiled an update. Genedrive plc has confirmed its latest six‑monthly block listing return,...

2M ago

Genedrive Reports No Share Issuance in Latest Block Listing Return

Genedrive ( ($GB:GDR) ) has provided an update. Genedrive plc has reported its latest six-monthly block listing return,...

2M ago

Genedrive reshapes board as major shareholder joins and long-serving chairman prepares exit

Genedrive ( ($GB:GDR) ) just unveiled an announcement. Genedrive has strengthened its governance by appointing major shareholder David...

2M ago

GDR FAQ

What was Genedrive PLC’s price range in the past 12 months?

Genedrive PLC lowest share price was 0.19 p and its highest was 1.50 p in the past 12 months.

What is Genedrive PLC’s market cap?

Genedrive PLC’s market cap is £16.86M.

When is Genedrive PLC’s upcoming earnings report date?

Genedrive PLC’s upcoming earnings report date is Nov 24, 2026 which is in 125 days.

How were Genedrive PLC’s earnings last quarter?

Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.

Is Genedrive PLC overvalued?

According to Wall Street analysts Genedrive PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genedrive PLC pay dividends?

Genedrive PLC does not currently pay dividends.

What is Genedrive PLC’s EPS estimate?

Genedrive PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genedrive PLC have?

Genedrive PLC has 1,605,568,200 shares outstanding.

What happened to Genedrive PLC’s price movement after its last earnings report?

Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.

Which hedge fund is a major shareholder of Genedrive PLC?

Currently, no hedge funds are holding shares in GB:GDR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genedrive PLC

Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.